José Luis Molinuevo
Molinuevo, José L.
VIAF ID: 305200298 (Personal)
Permalink: http://viaf.org/viaf/305200298
Preferred Forms
- 100 0 _ ‡a José Luis Molinuevo
- 100 1 _ ‡a Molinuevo, José L.
- 100 1 _ ‡a Molinuevo, José L.
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases | |
Early diagnosis and intervention in predementia Alzheimer's disease, 2013: | |
Multi-tracer model for staging cortical amyloid deposition using PET imaging | |
Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. | |
Naming is associated with left temporal pole metabolite levels in neurodegenerative diseases. | |
Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. | |
Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. | |
[New mutation in the PSEN1 (E120G) gene associated with early onset Alzheimer's disease]. | |
Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. | |
Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population | |
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected | |
Pallidotomy and quality of life in patients with Parkinson's disease: an early study. | |
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats | |
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study | |
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project | |
PICOGEN: five years experience with a genetic counselling program for dementia. | |
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers | |
Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations | |
Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. | |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. | |
A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease | |
Prepulse modulation of the startle reaction and the blink reflex in normal human subjects | |
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings | |
Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype | |
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis | |
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. | |
Problem-solving abilities and frontal lobe cortical thickness in healthy aging and mild cognitive impairment. | |
[Profile of the informal carer associated with the clinical management of the Alzheimer's disease patient refractory to symptomatic treatment of the disease]. | |
Psychometric Properties of the Memory Binding Test: Test-Retest Reliability and Convergent Validity. | |
Pure akinesia: an unusual phenotype of Hallervorden-Spatz syndrome | |
Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. | |
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. | |
Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis | |
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. | |
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update | |
Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family). | |
Regulatory issues. | |
Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham-controlled study. | |
Reply: To PMID 23794434. | |
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch | |
The roles of inflammation and immune mechanisms in Alzheimer's disease | |
Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. | |
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration | |
Secondary prevention of Alzheimer's dementia: neuroimaging contributions | |
Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. | |
Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. | |
Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection | |
Spanish multicenter normative studies (NEURONORMA project): normative data and equivalence of four BNT short-form versions. | |
Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort | |
Specific anatomic associations between white matter integrity and cognitive reserve in normal and cognitively impaired elders. | |
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers | |
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers | |
Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia | |
Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies | |
The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study. | |
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. | |
Therapy of behavioral disorders in Parkinson's disease. | |
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis | |
Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. | |
Usefulness of neurophysiologic techniques in stereotactic subthalamic nucleus stimulation for advanced Parkinson's disease. | |
Using artificial neural networks in clinical neuropsychology: high performance in mild cognitive impairment and Alzheimer's disease. | |
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort | |
Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls | |
Voxel based morphometry features and follow-up of amnestic patients at high risk for Alzheimer's disease conversion. | |
White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease | |
White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. | |
A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. | |
Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. |